

# Theo van der Kwast

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1744416/theo-van-der-kwast-publications-by-year.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

443 papers	34,425 citations	85 h-index	173 g-index
473 ext. papers	41,413 ext. citations	7.5 avg, IF	6.86 L-index

#	Paper	IF	Citations
443	Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge.. <i>Nature Medicine</i> , <b>2022</b> ,	50.5	14
442	The impact of grading scheme on non-muscle invasive bladder cancer progression: potential utility of hybrid grading schemes.. <i>Pathology</i> , <b>2022</b> ,	1.6	1
441	Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2022</b> , 40, 5.e1-5.e13	2.8	
440	Penile Extramammary Paget Disease Associated With Urothelial Carcinoma In Situ: Case Report And Literature Review.. <i>Journal of Cutaneous Pathology</i> , <b>2022</b> ,	1.7	
439	Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.. <i>European Radiology</i> , <b>2022</b> , 1	8	0
438	The telomere length landscape of prostate cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 6893	17.4	0
437	Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study. <i>PLoS ONE</i> , <b>2021</b> , 16, e0259272	3.7	0
436	Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors. <i>Cancer Research</i> , <b>2021</b> , 81, 5833-5848	10.1	2
435	Oncological benefit of re-resection for T1 bladder cancer: a comparative effectiveness study. <i>BJU International</i> , <b>2021</b> , 129, 258	5.6	0
434	Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse. <i>Nature Communications</i> , <b>2021</b> , 12, 6248	17.4	3
433	International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. <i>European Urology Focus</i> , <b>2021</b> ,	5.1	8
432	MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial. <i>Radiology</i> , <b>2021</b> , 298, 695-703	20.5	9
431	Prevalence of prostate cancer at autopsy in Nigeria-A preliminary report. <i>Prostate</i> , <b>2021</b> , 81, 553-559	4.2	1
430	Detection of clinically significant prostate cancer with F-DCFPyL PET/multiparametric MR. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 3702-3711	8.8	2
429	Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , <b>2021</b> ,	5.1	6
428	Reply to Rodolfo Montironi, Marina Scarpelli, Alessia Cimadamore, and Gregor Mikuz's Letter to the Editor re: Theo van der Kwast, Fredrik Liedberg, Peter C. Black, et al. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. <i>Eur Urol Focus</i> . In press. <a href="https://doi.org/10.1016/j.euf.2021.03.017">https://doi.org/10.1016/j.euf.2021.03.017</a> . Focus on Our Personal Recollections and Observations.	5.1	0
427	ISUP Consensus Definition of Cribriform Pattern Prostate Cancer. <i>American Journal of Surgical Pathology</i> , <b>2021</b> , 45, 1118-1126	6.7	6

425	Long-term use of 5-alpha-reductase inhibitors is safe and effective in men on active surveillance for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 69-76	6.2	3
424	Association between metformin medication, genetic variation and prostate cancer risk. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 96-105	6.2	7
423	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , <b>2021</b> , 79, 243-262	10.2	382
422	Artificial intelligence assistance significantly improves Gleason grading of prostate biopsies by pathologists. <i>Modern Pathology</i> , <b>2021</b> , 34, 660-671	9.8	22
421	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. <i>European Urology</i> , <b>2021</b> , 79, 263-282	10.2	186
420	Cribriform architecture prostatic adenocarcinoma in needle biopsies is a strong independent predictor for lymph node metastases in radical prostatectomy. <i>European Journal of Cancer</i> , <b>2021</b> , 148, 432-439	7.5	2
419	Intraductal carcinoma of the prostate is not a diagnostic entity. <i>Histopathology</i> , <b>2021</b> , 78, 342-344	7.3	3
418	Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. <i>Nature Cell Biology</i> , <b>2021</b> , 23, 87-98	23.4	53
417	Gleason grade 5 prostate cancer: sub-patterns and prognosis. <i>Pathology</i> , <b>2021</b> , 53, 3-11	1.6	1
416	Quantitative Prostate MRI Analysis Following Fluvastatin Therapy for Localized Prostate Cancer - A Pilot Study. <i>Canadian Association of Radiologists Journal</i> , <b>2021</b> , 72, 750-758	3.9	
415	Prostate cancer. <i>Nature Reviews Disease Primers</i> , <b>2021</b> , 7, 9	51.1	72
414	Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer. <i>Radiology</i> , <b>2021</b> , 300, 369-379	20.5	5
413	Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies. <i>World Journal of Urology</i> , <b>2021</b> , 1	4	2
412	Factors Associated with Re-resection in T1 Bladder Cancer: Identifying Patients Who Do Not Receive Guideline-Concordant Care at the Population Level. <i>Journal of Urology</i> , <b>2021</b> , 101097JU00000000000002229	2.5	
411	The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. <i>American Journal of Surgical Pathology</i> , <b>2021</b> , 45, 1007	6.7	0
410	Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy.. <i>European Urology</i> , <b>2021</b> ,	10.2	3
409	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. <i>American Journal of Surgical Pathology</i> , <b>2020</b> , 44, e15-e29	6.7	21

408	Report From the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. II. Molecular Pathology of Bladder Cancer: Progress and Challenges. <i>American Journal of Surgical Pathology</i> , <b>2020</b> , 44, e30-e46	6.7	16
407	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: IV: Current and Future Utilization of Molecular-Genetic Tests for Testicular Germ Cell Tumors. <i>American Journal of Surgical Pathology</i> , <b>2020</b> , 44, e66-e79	6.7	14
406	Intraductal carcinoma has a minimal impact on Grade Group assignment in prostate cancer biopsy and radical prostatectomy specimens. <i>Histopathology</i> , <b>2020</b> , 77, 742-748	7.3	9
405	Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted grading. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2020</b> , 477, 777-786	5.1	10
404	Granular necrosis: a distinctive form of cell death in malignant tumours. <i>Pathology</i> , <b>2020</b> , 52, 507-514	1.6	7
403	Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. <i>Canadian Urological Association Journal</i> , <b>2020</b> , 14, E373-E382	1.2	3
402	A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 630-637	6.2	17
401	Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada. <i>Bladder Cancer</i> , <b>2020</b> , 6, 363-392	1	0
400	The International Society of Urological Pathology Consultation on Molecular Pathology of Urogenital Cancer. <i>American Journal of Surgical Pathology</i> , <b>2020</b> , 44, 859-861	6.7	1
399	A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 603.e1-603.e7	2.8	7
398	Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer. <i>Nature Communications</i> , <b>2020</b> , 11, 441	17.4	21
397	Editorial Comment. <i>Journal of Urology</i> , <b>2020</b> , 203, 318	2.5	
396	Reply by Authors. <i>Journal of Urology</i> , <b>2020</b> , 204, 1194	2.5	
395	Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?. <i>Journal of Urology</i> , <b>2020</b> , 204, 1187-1194	2.5	5
394	Dataset for the reporting of urinary tract carcinoma-biopsy and transurethral resection specimen: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Modern Pathology</i> , <b>2020</b> , 33, 700-712	9.8	6
393	Comparison of Tumor Volume Parameters on Prostate Cancer Biopsies. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2020</b> ,	5	1
392	Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. <i>Lancet Oncology</i> , <b>2020</b> , 21, 222-232	21.7	154
391	Dataset for the reporting of carcinoma of the bladder-cystectomy, cystoprostatectomy and diverticulectomy specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2020</b> , 476, 521-534	5.1	9

390	Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1474-1494	2.2	66
389	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees. <i>European Urology</i> , <b>2020</b> , 77, 223-250	10.2	60
388	Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate: A Survey of Genitourinary Subspecialists. <i>American Journal of Surgical Pathology</i> , <b>2020</b> , 44, 673-680	6.7	16
387	Salvage radical prostatectomy following focal therapy: functional and oncological outcomes. <i>BJU International</i> , <b>2020</b> , 125, 525-530	5.6	16
386	The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. <i>American Journal of Surgical Pathology</i> , <b>2020</b> , 44, e87-e99	6.7	82
385	Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. <i>Eur Urol</i> 2020;78:304-6: Prebiopsy MRI: Through the Looking Glass. <i>European Urology</i> , <b>2020</b> , 78, 310-313	10.2	4
384	Borderline Gleason scores: communication is the key. <i>Journal of Clinical Pathology</i> , <b>2020</b> , 73, 616-617	3.9	1
383	Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1372-1380	13.4	44
382	Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations. <i>Pathology Research and Practice</i> , <b>2020</b> , 216, 153186	3.4	4
381	Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. <i>European Urology Oncology</i> , <b>2020</b> ,	6.7	6
380	Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003281	11.6	8
379	Methylation Markers in Prostate Biopsies Are Prognosticators for Late Biochemical Recurrence and Therapy after Surgery in Prostate Cancer Patients. <i>Journal of Molecular Diagnostics</i> , <b>2020</b> , 22, 30-39	5.1	3
378	An integrative DNA methylation model for improved prognostication of postsurgery recurrence and therapy in prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 39.e1-39.e9	2.8	6
377	Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. <i>European Urology Focus</i> , <b>2020</b> , 6, 231-234	5.1	44
376	Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups. <i>European Urology</i> , <b>2020</b> , 77, 191-198	10.2	31
375	Reply to Eva Comp�at, Mahul Amin, Victor Reuter's Editorial Reply re: Murali Varma, Brett Delahunt, Theodorus van der Kwast. Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. <i>Eur Urol</i> 2019;76:413-5: Precision Medicine Requires More Not Fewer Grade Categories. <i>European Urology</i> , <b>2020</b> , 77, e28-e29	10.2	
374	Genome-wide germline correlates of the epigenetic landscape of prostate cancer. <i>Nature Medicine</i> , <b>2019</b> , 25, 1615-1626	50.5	25
373	Handling and reporting of pelvic lymphadenectomy specimens in prostate and bladder cancer: a web-based survey by the European Network of Uropathology. <i>Histopathology</i> , <b>2019</b> , 74, 844-852	7.3	4

372	ONECUT2 is a driver of neuroendocrine prostate cancer. <i>Nature Communications</i> , <b>2019</b> , 10, 278	17.4	72
371	Long-term oncological outcomes of patients with paratesticular sarcoma. <i>BJU International</i> , <b>2019</b> , 124, 801-810	5.6	8
370	Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Histopathology</i> , <b>2019</b> , 75, 453-467	7.3	1
369	An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer. <i>Molecular Metabolism</i> , <b>2019</b> , 25, 119-130	8.8	28
368	The Proteogenomic Landscape of Curable Prostate Cancer. <i>Cancer Cell</i> , <b>2019</b> , 35, 414-427.e6	24.3	97
367	Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression. <i>Clinical Epigenetics</i> , <b>2019</b> , 11, 54	7.7	8
366	A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 104, 61-66	4	3
365	Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. <i>European Urology Oncology</i> , <b>2019</b> , 2, 88-96	6.7	3
364	Widespread and Functional RNA Circularization in Localized Prostate Cancer. <i>Cell</i> , <b>2019</b> , 176, 831-843.e23	36.2	214
363	A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. <i>European Urology</i> , <b>2019</b> , 76, 43-51	10.2	163
362	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). <i>European Urology</i> , <b>2019</b> , 76, 790-813	10.2	76
361	Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors. <i>Cancer Cell</i> , <b>2019</b> , 36, 674-689.e6	24.3	21
360	Are there differences between de novo and secondary upper tract urothelial carcinoma tumours?. <i>Canadian Urological Association Journal</i> , <b>2019</b> , E292-E299	1.2	
359	Accuracy of renal tumour biopsy for the diagnosis and subtyping of papillary renal cell carcinoma: analysis of paired biopsy and nephrectomy specimens with focus on discordant cases. <i>Journal of Clinical Pathology</i> , <b>2019</b> , 72, 363-367	3.9	2
358	EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. <i>Annals of Oncology</i> , <b>2019</b> , 30, 1697-1727	10.3	28
357	GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture. <i>European Urology Oncology</i> , <b>2019</b> , 2, 231-238	6.7	7
356	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. <i>European Urology Oncology</i> , <b>2019</b> , 2, 333-336	6.7	4
355	Data Set for the Reporting of Carcinoma of the Renal Pelvis and Ureter-Nephroureterectomy and Ureterectomy Specimens: Recommendations From the International Collaboration on Cancer Reporting (ICCR). <i>American Journal of Surgical Pathology</i> , <b>2019</b> , 43, e1-e12	6.7	3



354	Concordance of biopsy and prostatectomy diagnosis of intraductal and cribriform carcinoma in a prospectively collected data set. <i>Histopathology</i> , <b>2019</b> , 74, 474-482	7.3	23
353	SIU-ICUD on bladder cancer: pathology. <i>World Journal of Urology</i> , <b>2019</b> , 37, 41-50	4	8
352	Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 138-144	2.8	24
351	Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 103, 84-91	4	20
350	Grading of prostate cancer: a work in progress. <i>Histopathology</i> , <b>2019</b> , 74, 146-160	7.3	25
349	Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. <i>European Urology</i> , <b>2019</b> , 75, 699-702	10.2	5
348	Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up. <i>European Urology</i> , <b>2019</b> , 75, 374-377	10.2	10
347	Evolving concepts in prostatic neuroendocrine manifestations: from focal divergent differentiation to amphicrine carcinoma. <i>Human Pathology</i> , <b>2019</b> , 85, 313-327	3.7	14
346	Molecular landmarks of tumor hypoxia across cancer types. <i>Nature Genetics</i> , <b>2019</b> , 51, 308-318	36.3	255
345	Canadian Urological Association guideline: Muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , <b>2019</b> , 230-238	1.2	21
344	The mTOR Targets 4E-BP1/2 Restrain Tumor Growth and Promote Hypoxia Tolerance in PTEN-driven Prostate Cancer. <i>Molecular Cancer Research</i> , <b>2018</b> , 16, 682-695	6.6	18
343	The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression. <i>Cell</i> , <b>2018</b> , 173, 1003-1013.e15	56.2	115
342	Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma. <i>Journal of Urology</i> , <b>2018</b> , 200, 104-113	2.5	22
341	Utility of Pathology Imagebase for standardisation of prostate cancer grading. <i>Histopathology</i> , <b>2018</b> , 73, 8-18	7.3	19
340	Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trial. <i>European Radiology</i> , <b>2018</b> , 28, 4281-4287	8	19
339	Editorial Comment. <i>Journal of Urology</i> , <b>2018</b> , 199, 1509	2.5	
338	Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient-specific Molds to Correlate Images with Whole-mount Pathology. <i>European Urology</i> , <b>2018</b> , 73, 139	10.2	
337	Characteristics and outcome of prostate cancer patients with overall biopsy Gleason score 3+4=7 and highest Gleason score 3+4=7 or >3+4=7. <i>Histopathology</i> , <b>2018</b> , 72, 760-765	7.3	10

336	The New Realization About Cribriform Prostate Cancer. <i>Advances in Anatomic Pathology</i> , <b>2018</b> , 25, 31-37	5.1	42
335	Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. <i>Journal of Urology</i> , <b>2018</b> , 200, 1056-1061	2.5	1
334	Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19. <i>Cell</i> , <b>2018</b> , 174, 564-575	e18	56.2 154
333	Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. <i>BMC Cancer</i> , <b>2018</b> , 18, 8	4.8	54
332	Suspicious findings on micro-ultrasound imaging and early detection of prostate cancer. <i>Urology Case Reports</i> , <b>2018</b> , 16, 98-100	0.5	8
331	On cribriform prostate cancer. <i>Translational Andrology and Urology</i> , <b>2018</b> , 7, 145-154	2.3	14
330	The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. <i>BMC Urology</i> , <b>2018</b> , 18, 78	2.2	6
329	A feed forward loop enforces YAP/TAZ signaling during tumorigenesis. <i>Nature Communications</i> , <b>2018</b> , 9, 3510	17.4	37
328	Genomic hallmarks of localized, non-indolent prostate cancer. <i>Nature</i> , <b>2017</b> , 541, 359-364	50.4	320
327	Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. <i>Nature Communications</i> , <b>2017</b> , 8, 13671	17.4	128
326	Variant Histology and Clinicopathological Features of Prostate Cancer in Men Younger than 50 Years Treated with Radical Prostatectomy. <i>Journal of Urology</i> , <b>2017</b> , 198, 79-85	2.5	10
325	microRNAs and DICER1 are regulated by 1,25-dihydroxyvitamin D in prostate stroma. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2017</b> , 167, 192-202	5.1	20
324	MR elastography to measure the effects of cancer and pathology fixation on prostate biomechanics, and comparison with T <sub>2</sub> , T <sub>2</sub> * and ADC. <i>Physics in Medicine and Biology</i> , <b>2017</b> , 62, 1126-1148	3.8	8
323	The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. <i>European Urology</i> , <b>2017</b> , 72, 84-109	10.2	203
322	Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth. <i>European Urology</i> , <b>2017</b> , 72, 45-51	10.2	45
321	A Prostate Cancer "Nimbofus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , <b>2017</b> , 72, 665-674	10.2	98
320	Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer. <i>Modern Pathology</i> , <b>2017</b> , 30, 1126-1132	9.8	65
319	Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder Cancer. <i>Translational Oncology</i> , <b>2017</b> , 10, 168-177	4.9	22



318	Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	12
317	What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. <i>European Urology</i> , <b>2017</b> , 72, 250-266	10.2	218
316	Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: Analysis of a propensity score-matched cohort. <i>Canadian Urological Association Journal</i> , <b>2017</b> , 11, 41-46	1.2	7
315	Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2299-2305	2.2	153
314	LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression. <i>Cancer Research</i> , <b>2017</b> , 77, 5479-5490	10.1	53
313	Mitochondrial mutations drive prostate cancer aggression. <i>Nature Communications</i> , <b>2017</b> , 8, 656	17.4	66
312	Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors. <i>Oncology Letters</i> , <b>2017</b> , 14, 390-396	2.6	14
311	Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?. <i>Histopathology</i> , <b>2017</b> , 71, 926-933	7.3	13
310	TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. <i>Nature Genetics</i> , <b>2017</b> , 49, 1336-1345	36.3	105
309	Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 604.e17-604.e24	2.8	2
308	De klinische relevantie van cribriforme en intraductale prostaatkanker in diagnostische naaldbiopsien. <i>Tijdschrift Voor Urologie</i> , <b>2017</b> , 7, 168-177	0.2	
307	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. <i>European Urology</i> , <b>2017</b> , 72, 22-31	10.2	28
306	Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway. <i>Histopathology</i> , <b>2017</b> , 70, 281-289	7.3	26
305	Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance. <i>Journal of Urology</i> , <b>2017</b> , 197, 335-341	2.5	30
304	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , <b>2017</b> , 71, 618-629	10.2	1939
303	Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance. <i>Journal of Urology</i> , <b>2017</b> , 197, 75-83	2.5	32
302	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. <i>European Urology</i> , <b>2017</b> , 71, 630-642	10.2	924
301	The Clinical Genomics of Prostate Cancer <b>2017</b> , 97-110		1

300	Genomic architecture of radioresistant prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 26-26	2.2	
299	Integrated somatic subtypes of localized intermediate-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e560-e560	2.2	
298	A propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e16003-e16003	2.2	
297	Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer. <i>World Journal of Urology</i> , <b>2016</b> , 34, 253-60	4	9
296	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , <b>2016</b> , 8, 109	14.4	149
295	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. <i>Histopathology</i> , <b>2016</b> , 69, 441-9	7.3	55
294	Dynamic interplay between locus-specific DNA methylation and hydroxymethylation regulates distinct biological pathways in prostate carcinogenesis. <i>Clinical Epigenetics</i> , <b>2016</b> , 8, 32	7.7	16
293	Sonic hedgehog (Shh) signaling promotes tumorigenicity and stemness via activation of epithelial-to-mesenchymal transition (EMT) in bladder cancer. <i>Molecular Carcinogenesis</i> , <b>2016</b> , 55, 537-545	5	86
292	Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. <i>European Urology</i> , <b>2016</b> , 69, 802-20	10.2	52
291	Assessment of intravascular granulomas in testicular seminomas and their association with tumour relapse and dissemination. <i>Journal of Clinical Pathology</i> , <b>2016</b> , 69, 47-52	3.9	4
290	Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. <i>Journal of Molecular Diagnostics</i> , <b>2016</b> , 18, 395-406	5.1	40
289	Influence of Metabolic Syndrome on Prostate Cancer Stage, Grade, and Overall Recurrence Risk in Men Undergoing Radical Prostatectomy. <i>Urology</i> , <b>2016</b> , 93, 77-85	1.6	23
288	Impact of multidisciplinary bladder cancer care for muscle invasive bladder cancer: A propensity score matched analysis of survival outcomes.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 455-455	2.2	0
287	Characterization of Heterogeneous Prostate Tumors in Targeted Pten Knockout Mice. <i>PLoS ONE</i> , <b>2016</b> , 11, e0147500	3.7	12
286	Clonality of localized and metastatic prostate cancer. <i>Current Opinion in Urology</i> , <b>2016</b> , 26, 219-24	2.8	7
285	Technical Note: Method to correlate whole-specimen histopathology of radical prostatectomy with diagnostic MR imaging. <i>Medical Physics</i> , <b>2016</b> , 43, 1065-72	4.4	10
284	Lymph node staging in prostate cancer: perspective for the pathologist. <i>Journal of Clinical Pathology</i> , <b>2016</b> , 69, 1039-1045	3.9	10
283	Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy. <i>Modern Pathology</i> , <b>2016</b> , 29, 630-6	9.8	113

282	Human Microtumors Generated in 3D: Novel Tools for Integrated In Situ Studies of Cancer Immunotherapies. <i>Methods in Molecular Biology</i> , <b>2016</b> , 1393, 147-61	1.4	2
281	Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1311-6	10.3	36
280	Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma. <i>European Journal of Cancer</i> , <b>2016</b> , 66, 26-33	7.5	55
279	Effect of material property heterogeneity on biomechanical modeling of prostate under deformation. <i>Physics in Medicine and Biology</i> , <b>2015</b> , 60, 195-209	3.8	7
278	Diagnostic prostate biopsy performed in a non-academic center increases the risk of re-classification at confirmatory biopsy for men considering active surveillance for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2015</b> , 18, 69-74	6.2	4
277	Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates. <i>Journal of Urology</i> , <b>2015</b> , 193, 1519-24	2.5	75
276	Young-age prostate cancer. <i>Journal of Clinical Pathology</i> , <b>2015</b> , 68, 511-5	3.9	35
275	Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. <i>Modern Pathology</i> , <b>2015</b> , 28, 457-64	9.8	170
274	Real-Time MRI-Guided Focused Ultrasound for Focal Therapy of Locally Confined Low-Risk Prostate Cancer: Feasibility and Preliminary Outcomes. <i>American Journal of Roentgenology</i> , <b>2015</b> , 205, W177-84	5.4	36
273	Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications. <i>Modern Pathology</i> , <b>2015</b> , 28, 695-705	9.8	26
272	Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. <i>European Urology</i> , <b>2015</b> , 67, 64-70	10.2	66
271	Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 85-94	2.8	89
270	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. <i>Modern Pathology</i> , <b>2015</b> , 28, 612-30	9.8	79
269	Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series. <i>Prostate</i> , <b>2015</b> , 75, 1277-84	4.2	40
268	Spatial genomic heterogeneity within localized, multifocal prostate cancer. <i>Nature Genetics</i> , <b>2015</b> , 47, 736-45	36.3	306
267	Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma and epithelium by 1,25-dihydroxyvitamin D in men with prostate cancer and an in vitro model. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2015</b> , 148, 156-65	5.1	36
266	Novel multiplex MethyLight protocol for detection of DNA methylation in patient tissues and bodily fluids. <i>Scientific Reports</i> , <b>2014</b> , 4, 4432	4.9	33
265	Prognostic prostate tissue biomarkers of potential clinical use. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2014</b> , 464, 293-300	5.1	26

264	EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. <i>European Urology</i> , <b>2014</b> , 65, 467-79	10.2	965
263	EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. <i>European Urology</i> , <b>2014</b> , 65, 124-37	10.2	1360
262	Evaluation and prognostic significance of ACAT1 as a marker of prostate cancer progression. <i>Prostate</i> , <b>2014</b> , 74, 372-80	4.2	39
261	The impact of the use of aspirin and other nonsteroidal anti-inflammatory drugs on the risk of prostate cancer detection on biopsy. <i>Urology</i> , <b>2014</b> , 84, 1073-80	1.6	1
260	Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly. <i>European Urology</i> , <b>2014</b> , 66, 841-8	10.2	46
259	Next-generation RNA sequencing of archival formalin-fixed paraffin-embedded urothelial bladder cancer. <i>European Urology</i> , <b>2014</b> , 66, 982-6	10.2	27
258	Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. <i>European Urology</i> , <b>2014</b> , 66, 619-22	10.2	43
257	Words of wisdom. Re: Modeling grade progression in an active surveillance study. <i>European Urology</i> , <b>2014</b> , 66, 389-90	10.2	
256	Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. <i>Lancet, The</i> , <b>2014</b> , 384, 2027-35	40	910
255	SeqControl: process control for DNA sequencing. <i>Nature Methods</i> , <b>2014</b> , 11, 1071-5	21.6	6
254	ShatterProof: operational detection and quantification of chromothripsis. <i>BMC Bioinformatics</i> , <b>2014</b> , 15, 78	3.6	42
253	Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 1610-6	7.5	95
252	Validation of stem cell markers in clinical prostate cancer: $\beta$ -integrin is predictive for non-aggressive disease. <i>Prostate</i> , <b>2014</b> , 74, 488-96	4.2	29
251	Re: Architectural heterogeneity and cribriform pattern predict adverse clinical outcome for Gleason grade 4 prostatic adenocarcinoma. <i>European Urology</i> , <b>2014</b> , 66, 174	10.2	1
250	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 1521-1532	21.7	218
249	Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists. <i>Annals of Diagnostic Pathology</i> , <b>2014</b> , 18, 333-42	2.2	35
248	A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2014</b> , 17, 252-8	6.2	57
247	Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice. <i>Journal of Pathology</i> , <b>2014</b> , 233, 148-58	9.4	20

246	Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists. <i>Histopathology</i> , <b>2014</b> , 65, 216-27	7.3	34
245	Downgrading of biopsy based Gleason score in prostatectomy specimens. <i>Journal of Clinical Pathology</i> , <b>2014</b> , 67, 313-8	3.9	15
244	Concordance between transrectal ultrasound guided biopsy results and radical prostatectomy final pathology: Are we getting better at predicting final pathology?. <i>Canadian Urological Association Journal</i> , <b>2014</b> , 8, 47-52	1.2	10
243	Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. In regard to Freedland et al. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 88, 237-40	4	4
242	Obesity is associated with larger prostate volume but not with worse urinary symptoms: analysis of a large multiethnic cohort. <i>Urology</i> , <b>2014</b> , 83, 81-7	1.6	20
241	Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression. <i>Journal of Urology</i> , <b>2014</b> , 192, 1088-93	2.5	6
240	Striated muscle in the prostatic apex: does the amount in radical prostatectomy specimens predict postprostatectomy urinary incontinence?. <i>Urology</i> , <b>2014</b> , 83, 888-92	1.6	7
239	A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression. <i>European Urology</i> , <b>2014</b> , 66, 406-13	10.2	27
238	Integrated analysis of epigenomic and genomic changes by DNA methylation dependent mechanisms provides potential novel biomarkers for prostate cancer. <i>Oncotarget</i> , <b>2014</b> , 5, 7858-69	3.3	16
237	NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer. <i>Oncotarget</i> , <b>2014</b> , 5, 11081-90	3.3	25
236	Using NBN to predict biochemical relapse following image-guided radiotherapy (IGRT) for intermediate-risk prostate cancer (IR-PCa).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 26-26	2.2	
235	Should follow-up biopsies for men on active surveillance for prostate cancer be restricted to limited templates?. <i>Urology</i> , <b>2013</b> , 82, 405-9	1.6	8
234	Guidelines on processing and reporting of prostate biopsies: the 2013 update of the pathology committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2013</b> , 463, 367-77	5.1	39
233	Pathological staging of bladder cancer. <i>Diagnostic Histopathology</i> , <b>2013</b> , 19, 366-375	0.7	1
232	Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. <i>European Urology</i> , <b>2013</b> , 64, 693-9	10.2	64
231	Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. <i>European Urology</i> , <b>2013</b> , 63, 379-85	10.2	63
230	A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. <i>European Urology</i> , <b>2013</b> , 63, 321-32	10.2	77
229	Prostate cancer: ESMO Consensus Conference Guidelines 2012. <i>Annals of Oncology</i> , <b>2013</b> , 24, 1141-62	10.3	109

228	Active surveillance for low-risk prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2013</b> , 85, 295-302	39
227	Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. <i>European Urology</i> , <b>2013</b> , 64, 530-9	10.2 66
226	Contemporary grading for prostate cancer: implications for patient care. <i>European Urology</i> , <b>2013</b> , 63, 892-901	10.2 69
225	4FISH-IF, a four-color dual-gene FISH combined with p63 immunofluorescence to evaluate NKX3.1 and MYC status in prostate cancer. <i>Journal of Histochemistry and Cytochemistry</i> , <b>2013</b> , 61, 500-9	3-4 5
224	Intraductal carcinoma of the prostate: precursor or aggressive phenotype of prostate cancer?. <i>Prostate</i> , <b>2013</b> , 73, 442-8	4-2 23
223	Defining the threshold for significant versus insignificant prostate cancer. <i>Nature Reviews Urology</i> , <b>2013</b> , 10, 473-82	5-5 82
222	Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue. <i>Cancer Prevention Research</i> , <b>2013</b> , 6, 483-94	3-2 73
221	Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 3450-61	12.9 22
220	TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 5202-9	12.9 34
219	An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps. <i>Histopathology</i> , <b>2013</b> , 63, 756-66	7-3 30
218	Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma. <i>Journal of Clinical Pathology</i> , <b>2013</b> , 66, 779-86	3-9 17
217	Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 1498-507	5.6 70
216	Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression. <i>Molecular and Cellular Proteomics</i> , <b>2013</b> , 12, 1589-601	7.6 59
215	Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 1050-8	9.7 164
214	Re: should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. <i>European Urology</i> , <b>2012</b> , 61, 220	10.2 2
213	A new and highly prognostic system to discern T1 bladder cancer substage. <i>European Urology</i> , <b>2012</b> , 61, 378-84	10.2 117
212	Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate cancer. <i>BJU International</i> , <b>2012</b> , 110, 980-6	5.6 31
211	Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. <i>BJU International</i> , <b>2012</b> , 110, 1169-76	5.6 48



210	Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2896-904	12.9	44
209	Clinicopathologic characteristics of 23 cases of invasive low-grade papillary urothelial carcinoma. <i>Urology</i> , <b>2012</b> , 80, 361-6	1.6	10
208	Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. <i>Epigenetics</i> , <b>2012</b> , 7, 1037-45	5.7	38
207	Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 1318-25	7.5	91
206	Prostate-cancer mortality at 11 years of follow-up. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 981-90	59.2	875
205	Anatomo-Pathology <b>2012</b> , 39-54		
204	Focal magnetic resonance guided focused ultrasound for prostate cancer: Initial North American experience. <i>Canadian Urological Association Journal</i> , <b>2012</b> , 6, 283	1.2	27
203	Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy. <i>Prostate</i> , <b>2012</b> , 72, 108-15	4.2	21
202	Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer. <i>Prostate</i> , <b>2012</b> , 72, 1295-305	4.2	10
201	Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. <i>Cancer</i> , <b>2012</b> , 118, 4053-62	6.4	90
200	Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer. <i>BJU International</i> , <b>2012</b> , 109, 70-6	5.6	20
199	Prostatic needle biopsies following primary high intensity focused ultrasound (HIFU) therapy for prostatic adenocarcinoma: histopathological features in tumour and non-tumour tissue. <i>Journal of Clinical Pathology</i> , <b>2012</b> , 65, 729-34	3.9	22
198	ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. <i>Modern Pathology</i> , <b>2012</b> , 25, 471-9	9.8	104
197	Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 34019-31	5.4	50
196	NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 308-16	12.9	38
195	The value of triple antibody (34β12 + p63 + AMACR) cocktail stain in radical prostatectomy specimens with crushed surgical margins. <i>Journal of Clinical Pathology</i> , <b>2012</b> , 65, 437-40	3.9	11
194	SU-E-J-95: Towards Optimum Boundary Conditions for Biomechanical Model Based Deformable Registration Using Intensity Based Image Matching for Prostate Correlative Pathology. <i>Medical Physics</i> , <b>2012</b> , 39, 3674	4.4	1
193	Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 4025-36	15.9	33

192 Nonneoplastic and Neoplastic Ureteral and Renal Pelvis Disease **2012**, 255-280

191	Determination of 1,25-dihydroxyvitamin D concentrations in human colon tissues and matched serum samples. <i>Anticancer Research</i> , <b>2012</b> , 32, 259-63	2.3	14
190	A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. <i>Journal of Urology</i> , <b>2011</b> , 185, 121-5	2.5	222
189	Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment. <i>BJU International</i> , <b>2011</b> , 107, 540-6	5.6	27
188	Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. <i>BJU International</i> , <b>2011</b> , 108, 24-30	5.6	90
187	Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. <i>BJU International</i> , <b>2011</b> , 108, E237-44	5.6	51
186	EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. <i>European Urology</i> , <b>2011</b> , 59, 61-71	10.2	1112
185	Impact of 5 $\alpha$ -reductase inhibitors on men followed by active surveillance for prostate cancer. <i>European Urology</i> , <b>2011</b> , 59, 509-14	10.2	46
184	EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. <i>European Urology</i> , <b>2011</b> , 59, 572-83	10.2	386
183	Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer. <i>European Urology</i> , <b>2011</b> , 59, 1026-31	10.2	39
182	The contemporary concept of significant versus insignificant prostate cancer. <i>European Urology</i> , <b>2011</b> , 60, 291-303	10.2	224
181	Reply to Stefano Fanti, Bernd Krause, Wolfgang Weber, et al's Letter to the Editor re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. <i>Eur Urol</i> <b>2011</b> , 59, 570-73. <i>European Urology</i> , <b>2011</b> , 60, 291-4	10.2	1
180	Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies. <i>Prostate</i> , <b>2011</b> , 71, 778-90	4.2	16
179	Association of tissue promoter methylation levels of APC, TGF $\beta$ , HOXD3 and RASSF1A with prostate cancer progression. <i>International Journal of Cancer</i> , <b>2011</b> , 129, 2454-62	7.5	77
178	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. <i>Modern Pathology</i> , <b>2011</b> , 24, 39-47	9.8	97
177	Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2011</b> , 8, 107-13	19.4	23
176	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. <i>Modern Pathology</i> , <b>2011</b> , 24, 16-25	9.8	171
175	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. <i>Modern Pathology</i> , <b>2011</b> , 24, 26-38	9.8	152

174	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. <i>Modern Pathology</i> , <b>2011</b> , 24, 6-15	9.8	183
173	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. <i>Modern Pathology</i> , <b>2011</b> , 24, 48-57	9.8	149
172	Metastatic clear cell renal cell carcinoma presenting as multiple colonic polyps. <i>International Journal of Surgical Pathology</i> , <b>2011</b> , 19, 791-4	1.2	5
171	DNA methylation of HOXD3 as a marker of prostate cancer progression. <i>Laboratory Investigation</i> , <b>2010</b> , 90, 1060-7	5.9	49
170	Expression and prognostic value of platelet-derived growth factor-AA and its receptor in nephroblastoma. <i>BJU International</i> , <b>2010</b> , 106, 1389-93	5.6	12
169	FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. <i>PLoS ONE</i> , <b>2010</b> , 5, e13821	3.7	219
168	Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 3011-8	12.9	89
167	Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features. <i>Radiology</i> , <b>2010</b> , 255, 485-94	20.5	220
166	Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors. <i>Journal of Urology</i> , <b>2010</b> , 184, 81-6	2.5	18
165	Prostate cancer localization with multispectral MRI using cost-sensitive support vector machines and conditional random fields. <i>IEEE Transactions on Image Processing</i> , <b>2010</b> , 19, 2444-55	8.7	85
164	Supervised and unsupervised methods for prostate cancer segmentation with multispectral MRI. <i>Medical Physics</i> , <b>2010</b> , 37, 1873-83	4.4	91
163	Detection rates of cancer, high grade PIN and atypical lesions suspicious for cancer in the European Randomized Study of Screening for Prostate Cancer. <i>European Journal of Cancer</i> , <b>2010</b> , 46, 3068-72	7.5	24
162	External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. <i>Lancet Oncology</i> , <b>2010</b> , 11, 1066-73	21.7	646
161	Pathological stage review is indicated in primary pT1 bladder cancer. <i>BJU International</i> , <b>2010</b> , 106, 206-11	11.6	42
160	False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. <i>American Journal of Surgical Pathology</i> , <b>2010</b> , 34, 35-43	6.7	101
159	Should Pathologists Diagnose Adenocarcinoma When They Encounter a Single Small Atypical Focus in a Prostate Biopsy?. <i>American Journal of Surgical Pathology</i> , <b>2010</b> , 34, 1072	6.7	
158	Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies. <i>American Journal of Surgical Pathology</i> , <b>2010</b> , 34, 169-77	6.7	39
157	Should pathologists routinely report prostate tumour volume? The prognostic value of tumour volume in prostate cancer. <i>European Urology</i> , <b>2010</b> , 57, 821-9	10.2	59

156	The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading. <i>European Urology</i> , <b>2010</b> , 57, 1052-7	10.2	57
155	Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies. <i>European Urology</i> , <b>2010</b> , 57, 256-66	10.2	43
154	Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy. <i>European Urology</i> , <b>2010</b> , 57, 1111-4	10.2	124
153	Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. <i>European Urology</i> , <b>2010</b> , 58, 433-41	10.2	131
152	Words of wisdom. Re: The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. <i>European Urology</i> , <b>2010</b> , 58, 796-7	10.2	1
151	Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. <i>PLoS ONE</i> , <b>2009</b> , 4, e4830	3.7	74
150	Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model. <i>PLoS ONE</i> , <b>2009</b> , 4, e5662	3.7	57
149	Is incidentally detected prostate cancer in patients undergoing radical cystoprostatectomy clinically significant?. <i>American Journal of Clinical Pathology</i> , <b>2009</b> , 131, 279-83	1.9	50
148	Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]). <i>European Urology</i> , <b>2009</b> , 55, 659-67	10.2	65
147	Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. <i>Journal of Magnetic Resonance Imaging</i> , <b>2009</b> , 30, 327-34	5.6	278
146	The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. <i>Journal of Pathology</i> , <b>2009</b> , 218, 104-12	9.4	40
145	High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. <i>Prostate</i> , <b>2009</b> , 69, 1091-100	4.2	71
144	Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?. <i>BJU International</i> , <b>2009</b> , 104, 41-7	5.6	29
143	Cytology and Urinary Markers for the Diagnosis of Bladder Cancer. <i>European Urology Supplements</i> , <b>2009</b> , 8, 536-541	0.9	31
142	Screening and prostate-cancer mortality in a randomized European study. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 1320-8	59.2	2828
141	Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling. <i>Current Opinion in Urology</i> , <b>2009</b> , 19, 516-21	2.8	22
140	Patients' perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison. <i>BJU International</i> , <b>2008</b> , 101, 1106-10	5.6	81
139	Can non-malignant biopsy features identify men at increased risk of biopsy-detectable prostate cancer at re-screening after 4 years?. <i>BJU International</i> , <b>2008</b> , 101, 283-8	5.6	16

138	Prostatic preneoplasia and beyond. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2008</b> , 1785, 156-81	11.2	15
137	Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. <i>European Urology</i> , <b>2008</b> , 54, 835-43	10.2	124
136	Single Prostatic Cancer Foci on Prostate Biopsy. <i>European Urology Supplements</i> , <b>2008</b> , 7, 549-556	0.9	3
135	Differential accumulation of hypericin in spheroids composed of T-24 transitional cell carcinoma cells expressing different levels of E-cadherin. <i>Journal of Urology</i> , <b>2008</b> , 179, 2014-9	2.5	11
134	How to combine the molecular profile with the clinicopathological profile of urothelial neoplastic lesions. <i>Scandinavian Journal of Urology and Nephrology</i> , <b>2008</b> , 175-84		3
133	Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. <i>Cancer Research</i> , <b>2008</b> , 68, 7541-9	10.1	78
132	Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2--sparse versus dense cancers. <i>Radiology</i> , <b>2008</b> , 249, 900-8	20.5	205
131	Targeting a single mismatched minor histocompatibility antigen with tumor-restricted expression eradicates human solid tumors. <i>Blood</i> , <b>2008</b> , 112, 1844-52	2.2	29
130	Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. <i>American Journal of Surgical Pathology</i> , <b>2008</b> , 32, 1503-12	6.7	107
129	Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. <i>Cancer</i> , <b>2008</b> , 112, 636-44	6.4	36
128	Thirty-five years of noninvasive bladder carcinoma: a plea for the use of papillary intraurothelial neoplasia as new terminology <b>2008</b> , 30, 309-15		1
127	Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics. <i>Prostate</i> , <b>2007</b> , 67, 154-61	4.2	36
126	Should we replace the Gleason score with the amount of high-grade prostate cancer?. <i>European Urology</i> , <b>2007</b> , 51, 931-9	10.2	40
125	FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. <i>European Urology</i> , <b>2007</b> , 52, 760-8	10.2	67
124	Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening. <i>European Urology</i> , <b>2007</b> , 52, 89-97	10.2	86
123	Renal oncocytoma, yet another tumour that does not fit in the dualistic benign/malignant paradigm?. <i>Journal of Clinical Pathology</i> , <b>2007</b> , 60, 585-6	3.9	30
122	Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4178-86	2.2	250
121	Adjuvant radiotherapy after surgery for pathologically advanced prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 5671-2	2.2	11

120	Low frequency of molecular changes and tumor recurrence in inverted papillomas of the urinary tract. <i>American Journal of Surgical Pathology</i> , <b>2007</b> , 31, 938-46	6.7	31
119	Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. <i>American Journal of Roentgenology</i> , <b>2007</b> , 189, 323-8	5.4	461
118	Tumour features in the control and screening arm of a randomized trial of prostate cancer. <i>European Urology</i> , <b>2006</b> , 50, 70-5	10.2	28
117	Infrequent microsatellite instability in urothelial cell carcinoma of the bladder in young patients. <i>European Urology</i> , <b>2006</b> , 49, 685-90	10.2	11
116	The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. <i>European Urology</i> , <b>2006</b> , 50, 258-65	10.2	99
115	Does PSA velocity predict prostate cancer in pre-screened populations?. <i>European Urology</i> , <b>2006</b> , 49, 460-5; discussion 465	10.2	65
114	Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. <i>European Urology</i> , <b>2006</b> , 50, 475-82	10.2	53
113	The high post-test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant. <i>Diagnostic Cytopathology</i> , <b>2006</b> , 34, 523-7	1.4	30
112	Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer. <i>International Journal of Cancer</i> , <b>2006</b> , 118, 2538-42	7.5	11
111	Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. <i>International Journal of Cancer</i> , <b>2006</b> , 119, 1212-5	7.5	67
110	Gleason score, age and screening: modeling dedifferentiation in prostate cancer. <i>International Journal of Cancer</i> , <b>2006</b> , 119, 2366-71	7.5	58
109	Discrimination between nontumor bladder tissue and tumor by Raman spectroscopy. <i>Analytical Chemistry</i> , <b>2006</b> , 78, 7761-9	7.8	131
108	Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam. <i>Urology</i> , <b>2006</b> , 68, 615-20	1.6	25
107	Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. <i>American Journal of Surgical Pathology</i> , <b>2006</b> , 30, 684-93	6.7	131
106	Low-grade intraductal carcinoma of salivary gland: report of 3 cases with marked apocrine differentiation. <i>American Journal of Surgical Pathology</i> , <b>2006</b> , 30, 1014-21	6.7	84
105	Screening for prostate cancer without digital rectal examination and transrectal ultrasound: results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. <i>Prostate</i> , <b>2006</b> , 66, 625-31	4.2	25
104	Gene expression profiling of the human prostate zones. <i>BJU International</i> , <b>2006</b> , 98, 886-97	5.6	58
103	Microsatellite instability and mutation analysis of candidate genes in urothelial cell carcinomas of upper urinary tract. <i>Oncogene</i> , <b>2006</b> , 25, 2113-8	9.2	34



102	Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2006</b> , 449, 428-34	5.1	80
101	Web-based virtual microscopy in teaching and standardizing Gleason grading. <i>Human Pathology</i> , <b>2005</b> , 36, 381-6	3.7	74
100	A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation. <i>Human Pathology</i> , <b>2005</b> , 36, 981-6	3.7	63
99	Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men. <i>Urology</i> , <b>2005</b> , 65, 745-9	1.6	61
98	Prognostic markers in nephroblastoma (Wilms' tumor). <i>Urology</i> , <b>2005</b> , 65, 1047-54	1.6	25
97	Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer. <i>European Urology</i> , <b>2005</b> , 48, 153-61	10.2	30
96	Urine markers for bladder cancer surveillance: a systematic review. <i>European Urology</i> , <b>2005</b> , 47, 736-48	10.2	372
95	High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer. <i>Genes Chromosomes and Cancer</i> , <b>2005</b> , 44, 438-49	5	77
94	Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years. <i>Cancer</i> , <b>2005</b> , 103, 708-16	6.4	23
93	Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. <i>Cancer Research</i> , <b>2005</b> , 65, 5730-9	10.1	168
92	MIB-1 (KI-67) proliferation index and cyclin-dependent kinase inhibitor p27(Kip1) protein expression in nephroblastoma. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 591-7	12.9	23
91	Handling and pathology reporting of prostate biopsies. <i>European Urology</i> , <b>2004</b> , 46, 177-81	10.2	58
90	Lesions predictive for prostate cancer in a screened population: first and second screening round findings. <i>Prostate</i> , <b>2004</b> , 61, 260-6	4.2	44
89	Evaluation of genetic patterns in different tumor areas of intermediate-grade prostatic adenocarcinomas by high-resolution genomic array analysis. <i>Genes Chromosomes and Cancer</i> , <b>2004</b> , 39, 249-56	5	46
88	Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years. <i>Cancer</i> , <b>2004</b> , 100, 968-75	6.4	17
87	Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. <i>Human Molecular Genetics</i> , <b>2004</b> , 13, 1303-13	5.6	158
86	FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. <i>Cancer Research</i> , <b>2004</b> , 64, 1911-4	10.1	180
85	Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 1912-21	2.2	259

84	Androgen pathway dysregulation in BRCA1-mutated breast tumors. <i>Breast Cancer Research and Treatment</i> , <b>2003</b> , 79, 121-7	4.4	23
83	Morphological assessment of radical prostatectomy specimens. A protocol with clinical relevance. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2003</b> , 442, 211-7	5.1	31
82	Handling and pathology reporting of radical prostatectomy specimens. <i>European Urology</i> , <b>2003</b> , 44, 626-36.2	36.2	61
81	Androgen-independent expression of adrenomedullin and peptidylglycine alpha-amidating monooxygenase in human prostatic carcinoma. <i>Molecular Carcinogenesis</i> , <b>2003</b> , 38, 14-24	5	15
80	Genetic evaluation of localized prostate cancer in a cohort of forty patients: gain of distal 8q discriminates between progressors and nonprogressors. <i>Laboratory Investigation</i> , <b>2003</b> , 83, 789-96	5.9	32
79	Epidermal growth factor receptor regulates normal urothelial regeneration. <i>Laboratory Investigation</i> , <b>2003</b> , 83, 1333-41	5.9	29
78	A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. <i>International Journal of Cancer</i> , <b>2002</b> , 102, 91-5	7.5	157
77	Functions of epidermal growth factor-like growth factors during human urothelial reepithelialization in vitro and the role of erbB2. <i>Urological Research</i> , <b>2002</b> , 30, 240-7		22
76	Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2002</b> , 440, 3-11	5.1	87
75	Serendipity in detecting disease in low prostate-specific antigen ranges. <i>BJU International</i> , <b>2002</b> , 89, 384-9	5.6	22
74	Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. <i>Prostate</i> , <b>2002</b> , 50, 203-15	4.2	46
73	Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. <i>European Journal of Human Genetics</i> , <b>2002</b> , 10, 819-24	5.3	121
72	International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 3206-12	2.2	182
71	Prostatic intraepithelial neoplasia and putative precursor lesions of prostate cancer: a clinical perspective. <i>BJU International</i> , <b>2001</b> , 88, 147-57	5.6	18
70	Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml). <i>Prostate</i> , <b>2001</b> , 47, 252-61	4.2	35
69	Microsatellite analysis--DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial. <i>Cancer</i> , <b>2001</b> , 92, 768-75	6.4	65
68	Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erb B-2 in nephroblastoma. <i>Cancer</i> , <b>2001</b> , 92, 3120-9	6.4	38
67	Peptidylglycine alpha-amidating monooxygenase- and proadrenomedullin-derived peptide-associated neuroendocrine differentiation are induced by androgen deprivation in the neoplastic prostate. <i>International Journal of Cancer</i> , <b>2001</b> , 94, 28-34	7.5	16

66	Influence of the microenvironment on invasiveness of human bladder carcinoma cell lines. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2001</b> , 439, 552-9	5.1	17
65	Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features. <i>American Journal of Pathology</i> , <b>2001</b> , 158, 399-406	5.8	66
64	Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. <i>American Journal of Pathology</i> , <b>2001</b> , 158, 1955-9	5.8	370
63	Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. <i>Vaccine</i> , <b>2001</b> , 19, 3700-9	4.9	133
62	Nerve outgrowth and neuropeptide expression during the remodeling of human burn wound scars. A 7-month follow-up study of 22 patients. <i>Burns</i> , <b>2001</b> , 27, 717-22	2.3	44
61	Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination. <i>Urology</i> , <b>2001</b> , 57, 83-90	1.6	91
60	Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines. <i>Prostate</i> , <b>2000</b> , 42, 34-44	4.2	79
59	Staging prostate cancer. <i>Microscopy Research and Technique</i> , <b>2000</b> , 51, 423-9	2.8	30
58	Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region. <i>Laboratory Investigation</i> , <b>2000</b> , 80, 1291-8	5.9	45
57	Fixation-dependent immunolocalization shift and immunoreactivity of intracellular growth factors in cartilage. <i>The Histochemical Journal</i> , <b>2000</b> , 32, 391-6		6
56	Detection of prostate cancer: a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy. <i>Urology</i> , <b>2000</b> , 56, 617-21	1.6	67
55	Cellular and molecular pathology of prostate cancer precursors. <i>Scandinavian Journal of Urology and Nephrology</i> , <b>2000</b> , 19-43		52
54	HISTOPATHOLOGICAL PROSTATE CANCER CHARACTERISTICS AT RADICAL PROSTATECTOMY AFTER POPULATION BASED SCREENING. <i>Journal of Urology</i> , <b>2000</b> , 164, 411-415	2.5	39
53	Epidermal participation in post-burn hypertrophic scar development. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>1999</b> , 434, 221-6	5.1	27
52	Evaluation of prostate needle biopsies in a population-based screening study. <i>Cancer</i> , <b>1999</b> , 85, 145-152	6.4	62
51	Down-regulation of CD44 expression in human prostatic carcinoma cell lines is correlated with DNA hypermethylation. <i>International Journal of Cancer</i> , <b>1999</b> , 80, 439-43	7.5	40
50	Decreased expression of CD44 in metastatic prostate cancer. <i>International Journal of Cancer</i> , <b>1999</b> , 84, 478-83	7.5	41
49	Expression of E-cadherin, alpha- & beta-catenin, and CD44V6 and the subcellular localization of E-cadherin and CD44V6 in normal epidermis and basal cell carcinoma. <i>Human Pathology</i> , <b>1999</b> , 30, 1328-35	3.7	25

48	Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. <i>Urology</i> , <b>1999</b> , 53, 523-9	1.6	51
47	Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. <i>American Journal of Pathology</i> , <b>1999</b> , 154, 543-51	5.8	49
46	Down-regulation of CD44 expression in human prostatic carcinoma cell lines is correlated with DNA hypermethylation <b>1999</b> , 80, 439		2
45	Longitudinal evaluation of cytogenetic aberrations in prostatic cancer: tumours that recur in time display an intermediate genetic status between non-persistent and metastatic tumours. <i>Journal of Pathology</i> , <b>1998</b> , 185, 273-83	9.4	7
44	Cycling activity of benign prostatic epithelial cells during long-term androgen blockade: evidence for self-renewal of luminal cells. <i>Journal of Pathology</i> , <b>1998</b> , 186, 406-9	9.4	15
43	Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. <i>Human Pathology</i> , <b>1998</b> , 29, 1005-12	3.7	56
42	Microvascular invasion in prostate cancer: prognostic significance in patients treated by radical prostatectomy for clinically localized carcinoma. <i>Urologia Internationalis</i> , <b>1998</b> , 60, 17-24	1.9	35
41	The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients. <i>Journal of Urology</i> , <b>1997</b> , 158, 1880-4; discussion 1884-5	2.5	24
40	The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. <i>Journal of Urology</i> , <b>1997</b> , 158, 171-4	2.5	88
39	In vitro modulation of implantation and intraepithelial expansion of bladder tumor cells by epidermal growth factor. <i>Experimental Cell Research</i> , <b>1997</b> , 235, 395-402	4.2	9
38	Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer. <i>World Journal of Urology</i> , <b>1997</b> , 15, 339-45	4	51
37	Expression and functions of EGF, FGF and TGFbeta-growth-factor family members and their receptors in invasive human transitional-cell-carcinoma cells. <i>International Journal of Cancer</i> , <b>1997</b> , 71, 284-91	7.5	30
36	Proliferation of gemistocytic cells and glial fibrillary acidic protein (GFAP)-positive oligodendroglial cells in gliomas: a MIB-1/GFAP double labeling study. <i>Acta Neuropathologica</i> , <b>1996</b> , 91, 99-103	14.3	20
35	Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate. <i>Urological Research</i> , <b>1995</b> , 22, 333-41		44
34	Determination of Ki-67 defined growth fraction by monoclonal antibody MIB-1 in formalin-fixed, paraffin-embedded prostatic cancer tissues. <i>Prostate</i> , <b>1995</b> , 27, 154-9	4.2	12
33	Developmental pattern and regulation by androgens of androgen receptor expression in the urogenital tract of the rat. <i>Molecular and Cellular Endocrinology</i> , <b>1995</b> , 113, 245-53	4.4	84
32	Modulation of intra-epithelial expansion of human T24 bladder-carcinoma cells in murine urothelium by growth factors and extracellular-matrix components. <i>International Journal of Cancer</i> , <b>1995</b> , 60, 707-11	7.5	7
31	The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy. <i>International Journal of Cancer</i> , <b>1995</b> , 62, 252-8	7.5	91

30	Interphase cytogenetics of prostatic adenocarcinoma and precursor lesions: analysis of 25 radical prostatectomies and 17 adjacent prostatic intraepithelial neoplasias. <i>Genes Chromosomes and Cancer</i> , <b>1995</b> , 12, 241-50	5	64
29	An in vitro model of urothelial regeneration: effects of growth factors and extracellular matrix proteins. <i>Journal of Pathology</i> , <b>1994</b> , 173, 283-91	9.4	31
28	Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo. <i>Cancer Genetics and Cytogenetics</i> , <b>1994</b> , 73, 60-4		34
27	Characterization of distinct functions for growth factors in murine transitional epithelial cells in primary organotypic culture. <i>Experimental Cell Research</i> , <b>1994</b> , 214, 510-8	4.2	28
26	Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiated carcinoma. <i>Human Pathology</i> , <b>1993</b> , 24, 819-32	3.7	187
25	Characterization of mouse urothelial cell lines in different phases of transitional-cell carcinogenesis. <i>International Journal of Cancer</i> , <b>1993</b> , 54, 1022-7	7.5	11
24	Do neuroendocrine cells in human prostate cancer express androgen receptor?. <i>Histochemistry</i> , <b>1993</b> , 100, 393-8		121
23	Hepatic rhabdomyomatous tumor: late sequel of a fetal rhabdomyomatous nephroblastoma. <i>Pediatric Pathology</i> , <b>1992</b> , 12, 449-56		5
22	Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer. <i>International Journal of Cancer</i> , <b>1992</b> , 52, 581-4	7.5	72
21	No N-ras mutations in human uveal melanoma: the role of ultraviolet light revisited. <i>British Journal of Cancer</i> , <b>1991</b> , 64, 411-3	8.7	36
20	Androgen receptors in endocrine-therapy-resistant human prostate cancer. <i>International Journal of Cancer</i> , <b>1991</b> , 48, 189-93	7.5	312
19	Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. <i>Molecular Endocrinology</i> , <b>1991</b> , 5, 1396-404		429
18	Epitope prediction and confirmation for the human androgen receptor: generation of monoclonal antibodies for multi-assay performance following the synthetic peptide strategy. <i>Biochimica Et Biophysica Acta - General Subjects</i> , <b>1991</b> , 1073, 23-32	4	83
17	Ultrastructural and immunohistochemical segregation of gemistocytic subsets. <i>Human Pathology</i> , <b>1991</b> , 22, 33-40	3.7	17
16	Monoclonal antibodies for immunohistochemical labeling of immunocompetent cells in frozen sections of rhesus monkey tissues. <i>Journal of Medical Primatology</i> , <b>1991</b> , 20, 386-393	0.7	14
15	Phenotypic and genotypic analysis of large-cell lymphomas, formerly classified as true histiocytic lymphoma: identification of an unusual group of tumors. <i>Leukemia Research</i> , <b>1990</b> , 14, 337-46	2.7	26
14	Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. <i>Journal of Pathology</i> , <b>1990</b> , 160, 329-32	9.4	75
13	Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens. <i>Urological Research</i> , <b>1990</b> , 18, 181-7		44

12	Ki-67 immunostaining in uveal melanoma. The effect of pre-enucleation radiotherapy. <i>Ophthalmology</i> , <b>1990</b> , 97, 1275-80	7.3	61
11	Characterization of polyclonal antibodies against the N-terminal domain of the human androgen receptor. <i>Molecular and Cellular Endocrinology</i> , <b>1989</b> , 67, 29-38	4.4	64
10	Primary cutaneous adenoid cystic carcinoma: case report, immunohistochemistry, and review of the literature. <i>British Journal of Dermatology</i> , <b>1988</b> , 118, 567-77	4	52
9	Detection of factor VIII/coagulant antigen in human liver tissue. <i>Nature</i> , <b>1983</b> , 303, 530-2	50.4	111
8	Differential responsiveness to H-2-subregion-coded antigens in graft versus host and host versus graft reactions. <i>Cellular Immunology</i> , <b>1981</b> , 57, 389-99	4.4	4
7	Migration of B lymphocytes in lymphoid organs of lethally irradiated, thymocyte-reconstituted mice. <i>Cell and Tissue Research</i> , <b>1980</b> , 212, 497-508	4.2	20
6	Differential responsiveness to Mls locus antigens in graft-versus-host and host-versus-graft reactions. <i>Cellular Immunology</i> , <b>1980</b> , 51, 215-25	4.4	9
5	Enhancement by prostaglandin E1 and essential fatty acid deficiency of the passive transfer of delayed hypersensitivity to PPD in rats. Comparison with effects on delayed hypersensitivity to SRBC in mice. <i>International Journal of Immunopharmacology</i> , <b>1979</b> , 1, 119-26		11
4	Secondary delayed type hypersensitivity to sheep red blood cells in mice: dependence on long-lived memory cells. <i>Cellular Immunology</i> , <b>1979</b> , 43, 94-102	4.4	10
3	Primary and secondary delayed-type hypersensitivity to minor histocompatibility antigens in the mouse. <i>Cellular Immunology</i> , <b>1979</b> , 47, 182-91	4.4	10
2	Secondary delayed-type hypersensitivity to sheep red blood cells in mice: a long-lived memory phenomenon. <i>Cellular Immunology</i> , <b>1977</b> , 34, 385-94	4.4	15
1	Reconstitution of the thymus dependent area in the spleen of lethally irradiated mice. A light and electron microscopical study of the T-cell microenvironment. <i>Cell and Tissue Research</i> , <b>1974</b> , 149, 43-60	4.2	82